RedHill Biopharma (RDHL) Operating Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has reported Operating Expenses for 12 consecutive years, with $4.8 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Operating Expenses fell 48.2% year-over-year to $4.8 million in Q2 2023; TTM through Jun 2023 was $27.4 million, a 41.47% decrease from a year earlier, with the FY2025 full-year figure at $8.2 million, up 26.56% from the prior year.
• Operating Expenses was $4.8 million for Q2 2023 at RedHill Biopharma, down from $6.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $20.6 million in Q2 2021 and troughed at $4.8 million in Q2 2023.
• A 5-year average of $10.0 million and a median of $9.2 million in 2020 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 122.37% in 2021 and sank 55.08% in 2022, its largest moves.
• Over 5 years, Operating Expenses stood at $6.4 million in 2019, then jumped by 112.48% to $13.6 million in 2020, then retreated by 8.43% to $12.5 million in 2021, then sank by 38.78% to $7.6 million in 2022, then sank by 37.31% to $4.8 million in 2023.
• The last three Operating Expenses figures came in at $4.8 million (Q2 2023), $6.9 million (Q1 2023), and $7.6 million (Q4 2022), per Business Quant data.